Labiche Lise A, Al-Senani Fahmi, Wojner Anne W, Grotta James C, Malkoff Marc, Alexandrov Andrei V
Center for Noninvasive Brain Perfusion Studies, Stroke Program, University of Texas, Houston Medical School, Houston, USA.
Stroke. 2003 Mar;34(3):695-8. doi: 10.1161/01.STR.0000055940.00316.6B. Epub 2003 Feb 13.
Early arterial recanalization can lead to dramatic recovery (DR) during intravenous tissue plasminogen activator (tPA) therapy. However, it remains unclear whether this clinical recovery is sustained 3 months after stroke.
We studied consecutive patients treated with intravenous tPA (0.9 mg/kg within 3 hours) who had M1 or proximal M2 middle cerebral artery occlusion on pretreatment transcranial Doppler according to previously validated criteria. Patients were continuously monitored for 2 hours after tPA bolus to determine complete, partial, or no early recanalization with the Thrombolysis in Brain Ischemia (TIBI) flow grading system. A neurologist obtained the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores independently of transcranial Doppler results. DR was defined as a total NIHSS score of 0 to 3 points, and early recovery (ER) was defined improvement by > or =10 points at 2 hours after tPA bolus. Good long-term outcome was defined as an NIHSS score of 0 to 2 or an mRS score of 0 to 1 at 3 months.
Fifty-four patients with proximal middle cerebral artery occlusion had a median prebolus NIHSS score of 16 (range, 6 to 28; 90% with > or =10 points). The tPA bolus was given at 130+/-32 minutes (median, 120 minutes; 57% treated within the first 2 hours). DR+ER was observed in 50% of patients with early complete recanalization (n=18), 17% with partial recanalization (n=18), and 0% with no early recanalization (n=18) (P=0.025). Overall, DR+ER was observed in 12 patients (22%), and 9 (75%) had good outcome at 3 months in terms of NIHSS (P=0.009) and mRS (P=0.006) scores compared with non-DR and non-ER patients. If early recanalization was complete, 50% of these patients had good outcome at 3 months, and 78% with DR+ER sustained early clinical benefit. If recanalization was partial, 44% had good long-term outcome, and 66% of patients with DR+ER sustained the benefit. If no early recanalization occurred, 22% had good long-term outcome despite the lack of DR within 2 hours of tPA bolus (P=0.046). Mortality was 11%, 11%, and 39% in patients with complete, partial, and no early recanalization, respectively (P=0.025). Reasons for not sustaining DR in patients with early recanalization were subsequent symptomatic intracranial hemorrhage and recurrent ischemic stroke.
DR or ER after recanalization within 2 hours after tPA bolus was sustained at 3 months in most patients (75%) in our study. Complete or partial early recanalization leads to better outcome at 3 months after stroke. Fewer patients achieve good long-term outcome without early recanalization.
早期动脉再通可在静脉注射组织型纤溶酶原激活剂(tPA)治疗期间带来显著恢复(DR)。然而,目前尚不清楚这种临床恢复在卒中后3个月是否能持续。
我们研究了连续接受静脉注射tPA(3小时内0.9mg/kg)治疗的患者,这些患者在治疗前经颅多普勒检查符合先前验证的标准,存在大脑中动脉M1段或近端M2段闭塞。在静脉推注tPA后对患者连续监测2小时,使用脑缺血溶栓(TIBI)血流分级系统确定早期完全再通、部分再通或无再通情况。神经科医生独立于经颅多普勒结果获取美国国立卫生研究院卒中量表(NIHSS)和改良Rankin量表(mRS)评分。DR定义为NIHSS总分0至3分,早期恢复(ER)定义为静脉推注tPA后2小时内改善≥10分。良好的长期预后定义为3个月时NIHSS评分为0至2分或mRS评分为0至1分。
54例大脑中动脉近端闭塞患者静脉推注前NIHSS评分中位数为16分(范围6至28分;90%患者评分≥10分)。静脉推注tPA的时间为130±32分钟(中位数120分钟;57%患者在最初2小时内接受治疗)。早期完全再通的患者中50%(n = 18)观察到DR + ER,部分再通患者中17%(n = 18)观察到,无早期再通患者中0%(n = 18)观察到(P = 0.025)。总体而言,12例患者(22%)观察到DR + ER,与非DR和非ER患者相比,9例(75%)患者3个月时在NIHSS(P = 0.009)和mRS(P = 0.006)评分方面有良好预后。如果早期再通完全,这些患者中有50%在3个月时有良好预后,78%有DR + ER的患者维持了早期临床获益。如果再通为部分性,44%有良好的长期预后,66%有DR + ER的患者维持了获益。如果未发生早期再通,尽管在静脉推注tPA后2小时内无DR,但22%的患者仍有良好的长期预后(P = 0.046)。完全、部分和无早期再通患者的死亡率分别为11%、11%和39%(P = 0.025)。早期再通患者未维持DR的原因是随后出现症状性颅内出血和复发性缺血性卒中。
在我们的研究中,大多数患者(75%)在静脉推注tPA后2小时内再通后的DR或ER在3个月时得以维持。早期完全或部分再通可使卒中后3个月有更好的预后。没有早期再通的情况下,实现良好长期预后的患者较少。